Kodiak Gas Services Inc. Common Stock vs Summit Therapeutics Inc — how do they compare? Kodiak Gas Services Inc. Common Stock trades at $53.66 (market cap $5.42B), while Summit Therapeutics Inc trades at $17.6 (market cap $13.71B). The key difference: Summit Therapeutics Inc is far larger — about 2.5× Kodiak Gas Services Inc. Common Stock's market cap, and Kodiak Gas Services Inc. Common Stock pays a 3.66% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kodiak Gas Services Inc. Common Stock for 1 Days and Summit Therapeutics Inc for 16 Days on average.
| KGS | SMMT | |
|---|---|---|
Market Cap | $5.42B | $13.71B |
Volume | 1,926,947 | 6,173,057 |
Sector | Energy | Health |
52-Week High | $76.27 | $26.38 |
52-Week Low | $32.95 | $12.43 |
Typical Hold Time | 1 Days | 16 Days |
Enterprise Value | $8.10B | $13.04B |
Dividend Yield | 3.66% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Summit Therapeutics (SMMT) trades at $17.44, down 2.84% on the day, with a bullish technical signal from moving averages and strong analyst support. The company shows no revenue but secured a major $2 billion strategic investment from AstraZeneca in September 2026 to advance its cancer drug ivonescimab, driving recent stock volatility and media attention. Financials reflect a pre-revenue biotech profile with significant losses, negative ROE of -192.5%, and cash flow supported by financing activities.
The outlook hinges on clinical success with ivonescimab, offering substantial upside to the $29.33 consensus price target if trials succeed, but high execution risk remains given the lack of revenue and deep losses. Investors face binary outcomes dependent on drug approval and commercialization timelines amid competitive oncology pressures.
Trailing returns across standard periods
Latest headlines on both assets
Kodiak Gas Services, Inc. is a Texas-based provider of large-horsepower contract natural gas compression services, operating a fleet of roughly 4.5 million revenue-generating horsepower for oil and gas producers and midstream companies across major US production basins, including the Permian, Eagle Ford, and DJ Basin.
Read more on KGS →Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →